Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome

Next Previous
Trial Profile

A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation

Most Recent Events

  • 25 Apr 2021 Results secondary analysis on the long-term impact of 12 weeks of sonidegib treatment on the size and number of NBCCS, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
  • 25 Apr 2021 Results evaluating the pharmacokinetics of sonidegib in patients with NBCCS, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
  • 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top